Freenome
Freenome develops blood-based cancer screening tests that combine multiomics biomarker analysis with artificial intelligence and machine learning. The company operates clinical validation programs and a CLIA laboratory to develop and process assays intended to detect cancer at early, treatable stages. Freenome partners with commercial and diagnostic organizations to scale testing and integrate molecular results with longitudinal real-world data.
Industries
Nr. of Employees
large (251-1000)
Patents
Methods and systems for detecting cancer via nucleic acid methylation analysis
US-12763168-B2
View DetailsMethods and systems for detecting colorectal cancer via nucleic acid methylation analysis
US-12410480-B2
View Details
Methods and systems for detecting cancer via nucleic acid methylation analysis
US-12763168-B2
View DetailsMethods and systems for detecting colorectal cancer via nucleic acid methylation analysis
US-12410480-B2
View DetailsProducts
Blood-based colorectal cancer screening test (FDA-approved)
An in vitro diagnostic blood test intended to detect molecular signals associated with colorectal cancer in average-risk adults aged 45 and older; positive results are recommended to be followed by colonoscopy.
Blood-based lung cancer screening test (laboratory-developed test)
A blood-based screening test intended for adults 50–80 with significant smoking history who have not completed low-dose CT screening; positive results are recommended to be followed up with low-dose CT.
SimpleScreen Lung
Blood-based lung cancer screening test included in the Freenome portfolio for health systems.
Freenome CRC Screening Blood Test
A blood-based test for the early detection of colorectal cancer utilizing a multiomics platform and an AI/ML-based model to detect specific methylation signatures in cell-free DNA.
Freenome Digital Health
EHR-native digital tools that help health systems identify eligible patients, engage patients and care teams, and integrate screening into routine care.
Blood-based colorectal cancer screening test (FDA-approved)
An in vitro diagnostic blood test intended to detect molecular signals associated with colorectal cancer in average-risk adults aged 45 and older; positive results are recommended to be followed by colonoscopy.
Blood-based lung cancer screening test (laboratory-developed test)
A blood-based screening test intended for adults 50–80 with significant smoking history who have not completed low-dose CT screening; positive results are recommended to be followed up with low-dose CT.
SimpleScreen Lung
Blood-based lung cancer screening test included in the Freenome portfolio for health systems.
Freenome CRC Screening Blood Test
A blood-based test for the early detection of colorectal cancer utilizing a multiomics platform and an AI/ML-based model to detect specific methylation signatures in cell-free DNA.
Freenome Digital Health
EHR-native digital tools that help health systems identify eligible patients, engage patients and care teams, and integrate screening into routine care.
Services
Processing and reporting of blood-based cancer screening tests through a CLIA laboratory infrastructure for commercial samples.
Linking molecular test results with longitudinal outcomes and integrating ordering/results with EHRs and patient navigation workflows to support screening programs.
Processing and reporting of blood-based cancer screening tests through a CLIA laboratory infrastructure for commercial samples.
Linking molecular test results with longitudinal outcomes and integrating ordering/results with EHRs and patient navigation workflows to support screening programs.
Expertise Areas
- Early cancer detection and screening
- Multiomics biomarker discovery
- Clinical trial design and execution for diagnostic tests
- Diagnostic assay development and automation
Key Technologies
- Multiomics analysis
- Circulating cell-free DNA methylation sequencing
- Machine learning and deep learning
- Next-generation sequencing (inferred)
News & Updates
SEC declared effective the Form S-4 registration statement relating to the proposed business combination between Perceptive Capital Solutions Corp and Freenome; Extraordinary General Meeting scheduled for July 9, 2026.
Business combination agreement announced to create a publicly listed company and raise institutional financing to advance the AI/ML-enabled multiomics platform and commercialization.
Announcement of the closing of the business combination and commencement of trading on Nasdaq under ticker FRNM, with proceeds to support screening portfolio, AI/ML platform, and commercial infrastructure.
Newsroom headline indicating FDA approval of the company's colorectal cancer blood-based screening test and a commercialization partnership for the U.S.
Closed business combination and commenced trading on Nasdaq to become a publicly traded company focused on blood-based early cancer detection.
Registration Statement on Form S-4 declared effective by the SEC for the proposed business combination.
SEC declared effective the Form S-4 registration statement relating to the proposed business combination between Perceptive Capital Solutions Corp and Freenome; Extraordinary General Meeting scheduled for July 9, 2026.
Business combination agreement announced to create a publicly listed company and raise institutional financing to advance the AI/ML-enabled multiomics platform and commercialization.
Announcement of the closing of the business combination and commencement of trading on Nasdaq under ticker FRNM, with proceeds to support screening portfolio, AI/ML platform, and commercial infrastructure.
Newsroom headline indicating FDA approval of the company's colorectal cancer blood-based screening test and a commercialization partnership for the U.S.
Closed business combination and commenced trading on Nasdaq to become a publicly traded company focused on blood-based early cancer detection.
Registration Statement on Form S-4 declared effective by the SEC for the proposed business combination.